That is, if very early data in a handful of patients are borne out in later, larger studies.

Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”

Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas

Presenting at conferences allows companies to showcase data on new drugs and secure licensing partners, as well as further investment by shareholders. But two presentations at the recent EHA conference had the opposite effect.